May 29, 2024 10:59 AM EDTUpdated May 30, 12:50 PM
R&D

J&J's ma­jor de­pres­sive dis­or­der drug hits end­points in Phase 3 tri­al

Katherine Lewin

News Reporter

John­son & John­son is con­tin­u­ing to build out its neu­ro­science pipeline with pos­i­tive topline da­ta for its ex­per­i­men­tal de­pres­sion and in­som­nia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

Benev­o­len­tAI CEO is out af­ter less than a year on the job

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times